ATRY Stock Overview
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ATRY from our risk checks.
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.95 |
| 52 Week High | €5.90 |
| 52 Week Low | €2.77 |
| Beta | 0.40 |
| 1 Month Change | -3.28% |
| 3 Month Change | -18.06% |
| 1 Year Change | -41.00% |
| 3 Year Change | -68.62% |
| 5 Year Change | -17.13% |
| Change since IPO | 84.38% |
Recent News & Updates
Recent updates
Is Atrys Health, S.A. (BME:ATRY) Trading At A 44% Discount?
Sep 09
The Returns At Atrys Health (BME:ATRY) Aren't Growing
Jun 27Returns On Capital Are Showing Encouraging Signs At Atrys Health (BME:ATRY)
Nov 26Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger
Aug 12Did You Miss Atrys Health's (BME:ATRY) Whopping 387% Share Price Gain?
Feb 02
Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate
Dec 11Shareholder Returns
| ATRY | ES Healthcare | ES Market | |
|---|---|---|---|
| 7D | -3.6% | 0.7% | -0.6% |
| 1Y | -41.0% | -7.7% | 9.9% |
Return vs Industry: ATRY underperformed the Spanish Healthcare industry which returned -8.3% over the past year.
Return vs Market: ATRY underperformed the Spanish Market which returned 11% over the past year.
Price Volatility
| ATRY volatility | |
|---|---|
| ATRY Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.7% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: ATRY's share price has been volatile over the past 3 months.
Volatility Over Time: ATRY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,865 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Atrys Health, S.A. Fundamentals Summary
| ATRY fundamental statistics | |
|---|---|
| Market cap | €224.01m |
| Earnings (TTM) | -€30.45m |
| Revenue (TTM) | €206.10m |
1.1x
P/S Ratio-7.4x
P/E RatioIs ATRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRY income statement (TTM) | |
|---|---|
| Revenue | €206.10m |
| Cost of Revenue | €148.96m |
| Gross Profit | €57.15m |
| Other Expenses | €87.59m |
| Earnings | -€30.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 27.73% |
| Net Profit Margin | -14.77% |
| Debt/Equity Ratio | 76.1% |
How did ATRY perform over the long term?
See historical performance and comparison